386 related articles for article (PubMed ID: 32119843)
1. Participation of CXCL1 in the glial cells during neuropathic pain.
Moraes TR; Elisei LS; Malta IH; Galdino G
Eur J Pharmacol; 2020 May; 875():173039. PubMed ID: 32119843
[TBL] [Abstract][Full Text] [Related]
2. Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice.
Chen G; Park CK; Xie RG; Berta T; Nedergaard M; Ji RR
Brain; 2014 Aug; 137(Pt 8):2193-209. PubMed ID: 24919967
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of CXCL1 and CXCR2 contributes to remifentanil-induced hypernociception via modulating spinal NMDA receptor expression and phosphorylation in rats.
Yang LH; Xu GM; Wang Y
Neurosci Lett; 2016 Jul; 626():135-41. PubMed ID: 26724371
[TBL] [Abstract][Full Text] [Related]
4. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons.
Zhang ZJ; Cao DL; Zhang X; Ji RR; Gao YJ
Pain; 2013 Oct; 154(10):2185-2197. PubMed ID: 23831863
[TBL] [Abstract][Full Text] [Related]
5. Anti-nociceptive Role of CXCL1 in a Murine Model of Peripheral Nerve Injury-induced Neuropathic Pain.
Cao L; Malon JT
Neuroscience; 2018 Feb; 372():225-236. PubMed ID: 29309879
[TBL] [Abstract][Full Text] [Related]
6. Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury.
Zhou C; Shi X; Huang H; Zhu Y; Wu Y
Anesth Analg; 2014 May; 118(5):1090-6. PubMed ID: 24686047
[TBL] [Abstract][Full Text] [Related]
7. Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2.
Cao DL; Zhang ZJ; Xie RG; Jiang BC; Ji RR; Gao YJ
Exp Neurol; 2014 Nov; 261():328-36. PubMed ID: 24852102
[TBL] [Abstract][Full Text] [Related]
8. Spinal microglia-derived TNF promotes the astrocytic JNK/CXCL1 pathway activation in a mouse model of burn pain.
Zhang R; Xu B; Zhang N; Niu J; Zhang M; Zhang Q; Chen D; Shi Y; Chen D; Liu K; Zhang X; Li N; Fang Q
Brain Behav Immun; 2022 May; 102():23-39. PubMed ID: 35143878
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation.
Choi SR; Beitz AJ; Lee JH
Biomed Pharmacother; 2019 Oct; 118():109299. PubMed ID: 31387001
[TBL] [Abstract][Full Text] [Related]
10. Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice.
Manjavachi MN; Passos GF; Trevisan G; Araújo SB; Pontes JP; Fernandes ES; Costa R; Calixto JB
Neuropharmacology; 2019 Jun; 151():136-143. PubMed ID: 30991054
[TBL] [Abstract][Full Text] [Related]
11. Levo
Dai WL; Bao YN; Fan JF; Li SS; Zhao WL; Yu BY; Liu JH
Reg Anesth Pain Med; 2020 Mar; 45(3):219-229. PubMed ID: 31898581
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury.
Piotrowska A; Rojewska E; Pawlik K; Kreiner G; Ciechanowska A; Makuch W; Nalepa I; Mika J
Front Immunol; 2019; 10():2198. PubMed ID: 31616413
[TBL] [Abstract][Full Text] [Related]
13. Spinal CXCL5 contributes to nerve injury-induced neuropathic pain via modulating GSK-3β phosphorylation and activity in rats.
Xu W; Zhu M; Yuan S; Yu W
Neurosci Lett; 2016 Nov; 634():52-59. PubMed ID: 27717828
[TBL] [Abstract][Full Text] [Related]
14. The astrocyte-targeted therapy by Bushi for the neuropathic pain in mice.
Shibata K; Sugawara T; Fujishita K; Shinozaki Y; Matsukawa T; Suzuki T; Koizumi S
PLoS One; 2011; 6(8):e23510. PubMed ID: 21876755
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model-
Piotrowska A; Ciapała K; Pawlik K; Kwiatkowski K; Rojewska E; Mika J
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681732
[TBL] [Abstract][Full Text] [Related]
16. RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain.
Tatsumi E; Yamanaka H; Kobayashi K; Yagi H; Sakagami M; Noguchi K
Glia; 2015 Feb; 63(2):216-28. PubMed ID: 25130721
[TBL] [Abstract][Full Text] [Related]
17. Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway.
Zhou L; Hu Y; Li C; Yan Y; Ao L; Yu B; Fang W; Liu J; Li Y
Neuropharmacology; 2018 Jun; 135():34-47. PubMed ID: 29518397
[TBL] [Abstract][Full Text] [Related]
18. Brain-derived neurotrophic factor contributes to spinal long-term potentiation and mechanical hypersensitivity by activation of spinal microglia in rat.
Zhou LJ; Yang T; Wei X; Liu Y; Xin WJ; Chen Y; Pang RP; Zang Y; Li YY; Liu XG
Brain Behav Immun; 2011 Feb; 25(2):322-34. PubMed ID: 20933591
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to the development of neuropathic pain.
Luo X; Tai WL; Sun L; Pan Z; Xia Z; Chung SK; Cheung CW
Mol Pain; 2016; 12():. PubMed ID: 27030717
[TBL] [Abstract][Full Text] [Related]
20. Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.
Taves S; Berta T; Liu DL; Gan S; Chen G; Kim YH; Van de Ven T; Laufer S; Ji RR
Brain Behav Immun; 2016 Jul; 55():70-81. PubMed ID: 26472019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
